8-K: Henry Schein Reports First Quarter 2025 Financial Results: EPS Up, Guidance Maintained

Henry Schein announced its first quarter 2025 financial results, reporting a GAAP diluted EPS increase of 22% and maintaining its 2025 financial guidance.

Summary

• Henry Schein reported its financial results for the first quarter ended March 29, 2025.
• First-quarter GAAP diluted EPS was $0.88, a 22% increase compared to Q1 2024.
• Non-GAAP diluted EPS was $1.15, a 4.5% increase compared to the same period last year.
• Total net sales for the quarter were $3.2 billion.
• Constant currency total net sales increased by 1.4% compared to the first quarter of 2024; excluding PPE and COVID test kits, the increase was 2.0%.
• The company repurchased $161 million of common stock, representing approximately 2.3 million shares.
• Henry Schein maintained its 2025 financial guidance, projecting non-GAAP diluted EPS of $4.80 to $4.94, sales growth of 2% to 4%, and mid-single-digit Adjusted EBITDA growth.
• The company expects to achieve annual run-rate savings at the high end of its $75 million to $100 million goal by the end of 2025 from restructuring efforts.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with growth in EPS and maintained guidance, but also acknowledges some challenges like currency headwinds and slower equipment sales.

Positives

• GAAP diluted EPS increased by 22% year-over-year.
• Non-GAAP diluted EPS increased by 4.5% year-over-year.
• The company is seeing momentum heading into the second quarter.
• The company is advancing its BOLD+1 Strategic Plan.
• The company repurchased $161 million of common stock.
• The company expects to achieve annual run-rate savings at the high end of its $75 million to $100 million goal by the end of 2025 from restructuring efforts.

Negatives

• As-reported total net sales decreased 0.1% due to a stronger U.S. dollar.
• Global Dental Distribution equipment sales decreased 2.4% in constant currencies.
• Monthly sales growth accelerated throughout the quarter after a slow start in January primarily as a result of weather-related events in the U.S.

Risks

• The company's performance is subject to various risks and uncertainties, including dependence on third parties, competition, changes in the healthcare industry, and global economic conditions.
• Cybersecurity risks, including the October 2023 incident, could impact the company's information systems and technology products.
• Fluctuations in foreign currency exchange rates could affect financial results.
• The company is exposed to risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters.

Future Outlook

Henry Schein maintains its 2025 financial guidance, expecting non-GAAP diluted EPS of $4.80 to $4.94, sales growth of 2% to 4%, and mid-single-digit Adjusted EBITDA growth.

Management Comments

• 'We are pleased with our first quarter financial results as well as the momentum we are seeing heading into the second quarter and remain confident in the fundamentals of our business,' said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
• Mr. Bergman added that the company remains committed to its long-term financial goal of high-single-digit to low-double-digit earnings growth by continuing to successfully execute against its strategy.

Industry Context

Henry Schein, as the world's largest provider of healthcare solutions to office-based dental and medical practitioners, is impacted by trends in patient traffic, technology adoption, and global economic conditions. The company's performance reflects the overall health of the dental and medical industries.

Comparison to Industry Standards

• Comparing Henry Schein's performance to competitors like Patterson Companies and McKesson Corporation would provide a more comprehensive view of its relative performance.
• Benchmarking against industry averages for sales growth and EPS would also be beneficial.
• The company's growth in dental and medical specialty businesses can be compared to the growth rates of specialized healthcare providers.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and stock repurchase program.
• Employees are affected by the company's restructuring plan and strategic initiatives.
• Customers benefit from the company's solutions and services.
• Suppliers and manufacturers are impacted by the company's purchasing decisions and global operations.

Next Steps

• The company will hold a conference call to discuss the results.
• Investors can listen to the conference call through Henry Schein's website.
• The company will be posting slides summarizing the results on its website.

Key Dates

Keywords

financial results, Henry Schein, EPS, sales growth, EBITDA, stock repurchase, healthcare solutions, dental, medical, distribution